methacetin has been researched along with Chronic Hepatitis C in 6 studies
methacetin: RN given refers to parent cpd
methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study was carried out to evaluate the role of 13C-methacetin breath test 13C-MBT) as a non invasive tool for liver fibrosis staging in patients with chronic hepatitis C (CHC)." | 9.19 | Role of 13C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C. ( Cristian, B; Fierbinteanu-Braticevici, C; Papacocea, R; Tribus, L, 2014) |
| "The (13)C-methacetin-breath test and also several noninvasive blood tests comprising routine laboratory parameters have been proposed to predict fibrosis and cirrhosis in chronic hepatitis C." | 7.74 | 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. ( Braden, B; Caspary, WF; Chapman, RW; Dietrich, CF; Dinesen, L; Sarrazin, C, 2008) |
| "Sixty-one healthy controls and 81 patients with chronic hepatitis C underwent a 13C-methacetin breath test." | 7.73 | 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. ( Braden, B; Caspary, WF; Dietrich, CF; Faust, D; Sarrazin, C; Sarrazin, U; Zeuzem, S, 2005) |
| " The present study was carried out to evaluate the role of 13C-methacetin breath test 13C-MBT) as a non invasive tool for liver fibrosis staging in patients with chronic hepatitis C (CHC)." | 5.19 | Role of 13C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C. ( Cristian, B; Fierbinteanu-Braticevici, C; Papacocea, R; Tribus, L, 2014) |
| "The (13)C-methacetin-breath test and also several noninvasive blood tests comprising routine laboratory parameters have been proposed to predict fibrosis and cirrhosis in chronic hepatitis C." | 3.74 | 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. ( Braden, B; Caspary, WF; Chapman, RW; Dietrich, CF; Dinesen, L; Sarrazin, C, 2008) |
| "Sixty-one healthy controls and 81 patients with chronic hepatitis C underwent a 13C-methacetin breath test." | 3.73 | 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. ( Braden, B; Caspary, WF; Dietrich, CF; Faust, D; Sarrazin, C; Sarrazin, U; Zeuzem, S, 2005) |
| "Chronic viral hepatitis B and C cause liver fibrosis, leading to cirrhosis." | 1.37 | Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. ( de Knegt, RJ; Francke, J; Hansen, BE; Kuipers, EJ; Stibbe, KJ; van Vuuren, AJ; Verveer, C; Zondervan, PE, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fierbinteanu-Braticevici, C | 1 |
| Papacocea, R | 1 |
| Tribus, L | 1 |
| Cristian, B | 1 |
| Lalazar, G | 1 |
| Pappo, O | 1 |
| Hershcovici, T | 1 |
| Hadjaj, T | 1 |
| Shubi, M | 1 |
| Ohana, H | 1 |
| Hemed, N | 1 |
| Ilan, Y | 1 |
| Stibbe, KJ | 1 |
| Verveer, C | 1 |
| Francke, J | 1 |
| Hansen, BE | 1 |
| Zondervan, PE | 1 |
| Kuipers, EJ | 1 |
| de Knegt, RJ | 1 |
| van Vuuren, AJ | 1 |
| Braden, B | 2 |
| Faust, D | 1 |
| Sarrazin, U | 1 |
| Zeuzem, S | 1 |
| Dietrich, CF | 2 |
| Caspary, WF | 2 |
| Sarrazin, C | 2 |
| Goetze, O | 1 |
| Selzner, N | 1 |
| Fruehauf, H | 1 |
| Fried, M | 1 |
| Gerlach, T | 1 |
| Mullhaupt, B | 1 |
| Dinesen, L | 1 |
| Chapman, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure[NCT02786836] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-10 | Completed | ||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT[NCT00294489] | 500 participants (Anticipated) | Observational | 2006-02-28 | Recruiting | |||
| Use of the BreathID to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients With Cirrhosis in Need of Liver Transplantation[NCT00375011] | 200 participants (Anticipated) | Observational | 2008-09-30 | Terminated (stopped due to Company restructured and protocol restructured. Resubmitted with IDE approval under new company name-Exalenz) | |||
| Use of the BreathID Methacetin Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients Awaiting Liver Transplantation[NCT01157845] | Phase 3 | 165 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT/transplant free survival at Day 21 | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 1.4 | 0.2 |
Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: Days 1 and 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Mean Peak PDR for TFS subjects at Day 21 | Mean Peak PDR for non-TFS subjects at Day 21 | |
| 13C-Methacetin Breath Test (MBT) | 10.2 | 1.9 |
This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT & Day 21 TFS | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 9.1 | 2.3 |
Patient experiences complications of liver failure within 1 year of study entry and undergoes liver transplantation (NCT01157845)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Laboratory Assay | 34 |
Patient dies of liver-related causes within 1 year of study entry (NCT01157845)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| Laboratory Assay | 11 |
1 trial available for methacetin and Chronic Hepatitis C
| Article | Year |
|---|---|
Role of 13C methacetin breath test for non invasive staging of liver fibrosis in patients with chronic hepatitis C.
Topics: Acetamides; Area Under Curve; Breath Tests; Carbon Isotopes; Enzyme-Linked Immunosorbent Assay; Fema | 2014 |
5 other studies available for methacetin and Chronic Hepatitis C
| Article | Year |
|---|---|
A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT.
Topics: Acetamides; Adult; Aged; Alanine Transaminase; Algorithms; Breath Tests; Carbon Isotopes; Female; He | 2008 |
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
Topics: Acetamides; Adult; Aspartate Aminotransferases; Biomarkers; Blood Platelets; Breath Tests; Elasticit | 2011 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection.
Topics: Acetamides; Adult; Aged; Breath Tests; Carbon Radioisotopes; Case-Control Studies; Female; Hepatitis | 2005 |
13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry.
Topics: Acetamides; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis C, Chronic; Humans; Liver Cirrho | 2007 |
13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry.
Topics: Acetamides; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis C, Chronic; Humans; Liver Cirrho | 2007 |
13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry.
Topics: Acetamides; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis C, Chronic; Humans; Liver Cirrho | 2007 |
13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry.
Topics: Acetamides; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis C, Chronic; Humans; Liver Cirrho | 2007 |
13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.
Topics: Acetamides; Adult; Aged; Biopsy, Needle; Breath Tests; Cohort Studies; Disease Progression; Female; | 2008 |